Source: https://www.scribd.com/document/123169818/fda-1571
Timestamp: 2017-12-18 22:36:03
Document Index: 150268293

Matched Legal Cases: ['art 312', 'art 312', 'art 314', 'art 314', 'art 601', 'art 56', 'art 2']

fda 1571 | Clinical Trial | Food And Drug Administration
Uploaded by Nitin Kashyap
Description: see it..
Form Approved: OMB No. 0910-0014 Expiration Date: April 30, 2015 See PRA Statement on page 2.
NOTE: No drug/biologic may be shipped or clinical investigation begun until an IND for that investigation is in effect (21 CFR 312.40)
(Title 21, Code of Federal Regulations (CFR) Part 312)
1. Name of Sponsor 3. Sponsor Address
Address 1 (Street address, P.O. box, company name c/o) Address 2 (Apartment, suite, unit, building, floor, etc.) City Country State/Province/Region ZIP or Postal Code
2. Date of Submission (mm/dd/yyyy) 4. Telephone Number (Include country code if applicable and area code)
5. Name(s) of Drug (Include all available names: Trade, Generic, Chemical, or Code)
Continuation Page for #5
6. IND Number (If previously assigned)
7. (Proposed) Indication for Use
Is this indication for a rare disease (prevalence <200,000 in U.S.)? Does this product have an FDA Orphan Designation for this indication? Yes No If yes, provide the Orphan Designation number for this indication:
Continuation Page for #7
9. List numbers of all Investigational New Drug Applications (21 CFR Part 312), New Drug Applications (21 CFR Part 314) , Drug Master Files (21 CFR Part 314.420) , and Biologics License Applications (21 CFR Part 601) referred to in this application.
10. IND submission should be consecutively numbered. The initial IND should be numbered “Serial number: 0000.” The next submission (e.g., amendment, report, or correspondence) should be numbered “Serial Number: 0001.” Subsequent submissions should be numbered consecutively in the order in which they are submitted.. 11. This submission contains the following (Select all that apply)
Initial Investigational New Drug Application (IND) Request For Reactivation Or Reinstatement Development Safety Update Report (DSUR) Response to Clinical Hold Annual Report Other (Specify):
Response To FDA Request For Information General Correspondence
New Protocol Change in Protocol New Investigator PMR/PMC Protocol
Information Amendment(s)
Chemistry/Microbiology Pharmacology/Toxicology Clinical Statistics Clinical Pharmacology
Meeting Proprietary Name Review Special Protocol Assessment Formal Dispute Resolution
IND Safety Report(s)
Initial Written Report Follow-up to a Written Report
12. Select the following only if applicable. (Justification statement must be submitted with application for any items selected below. Refer to the cited CFR section for further information.) Expanded Access Use, 21 CFR 312.300
Emergency Research Exception From Informed Consent Requirements, 21 CFR 312.23 (f) Charge Request, 21 CFR 312.8 Individual Patient, NonEmergency 21 CFR 312.310 Individual Patient, Emergency 21 CFR 312.310(d) Intermediate Size Patient Population, 21 CFR 312.315 Treatment IND or Protocol, 21 CFR 312.320
For FDA Use Only
CBER/DCC Receipt Stamp DDR Receipt Stamp Division Assignment
IND Number Assigned
FORM FDA 1571 (10/12)
Facilities data (21 CFR 312. Send comments regarding this burden estimate or any other aspect of this information collection. etc. Telephone Number of Alternate Contact (Include country code if applicable and area code) 25. and a listing of the obligations transferred (use continuation page). box. a collection of information unless it displays a currently valid OMB number. Investigator’s brochure (21 CFR 312.23(a)(6)) b. Investigator data (21 CFR 312. Signature Of Sponsor or Sponsor’s Authorized Representative Sign WARNING : A willfully false statement is a criminal offense (U.23(a)(3)) 5.23(a)(2)) 3. Clinical Trials Certification of Compliance (Form FDA 3674) Yes Yes No No Continuation Page for #14 14. Contents of Application – This application contains the following items (Select all that apply) 1. Protocol(s) (21 CFR 312.S.23(a)(3)) 4. building. Email Address 22. 17. Study protocol(s) (21 CFR 312. Name of Alternate Contact 24. Institutional Review Board data (21 CFR 312. I agree to conduct the investigation in accordance with all other applicable regulatory requirements. P. suite. Table of Contents (21 CFR 312.23(a)(6)(iii) (b)) or completed Form(s) FDA 1572 7. and a person is not required to respond to. Chemistry. company name c/o) Address 2 (Apartment. and control data (21 CFR 312. MD 20850 DO NOT SEND YOUR COMPLETED FORM TO THIS PRA STAFF ADDRESS. FORM FDA 1571 (10/12) Page 2 of 2 . 1001). including the time to review instructions.C. Room 400 Rockville. Telephone Number (Include country code if applicable and area code) 20. Introductory statement (21 CFR 312. Pharmacology and toxicology data (21 CFR 312. Biosimilar User Fee Cover Sheet (Form FDA 3792) 12.23(a)(6)(iii)(b)) or completed Form(s) FDA 1572 c. The information below applies only to requirements of the Paperwork Reduction Act of 1995. Title 18. Form FDA 1571 (21 CFR 312. Date of Signature (mm/dd/yyyy) 23. Sec. floor.23(a)(5)) 6. Address Address 1 (Street address. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold or financial hold. Facsimile (FAX) Number (Include country code if applicable and area code) 21. gather and maintain the data needed and complete and review the collection of information. Name(s) and Title(s) of the person(s) responsible for review and evaluation of information relevant to the safety of the drug I agree not to begin clinical investigations until 30 days after FDA’s receipt of the IND unless I receive earlier notification by FDA that the studies may begin. Previous human experience (21 CFR 312.23(a)(10)) 11.23(a)(8)) 9.23(a)(6)) a. provide a statement containing the name and address of the contract research organization. General Investigational plan (21 CFR 312. The burden time for this collection of information is estimated to average 100 hours per response.23(a)(6)(iii)(b)) or completed Form(s) FDA 1572 6.” Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff 1350 Piccard Drive. I agree that an Institutional Review Board (IRB) that complies with the requirements set forth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation.O. unit. Name and Title of the person responsible for monitoring the conduct and progress of the clinical investigations 16.Previous Page Next Page 13. Additional information (21 CFR 312.) City Country State/Province/Region ZIP or Postal Code 19. will any sponsor obligations be transferred to the contract research organization? If Yes. identification of the clinical study. Name Of Sponsor or Sponsor’s Authorized Representative 18. 15. Is any part of the clinical study to be conducted by a contract research organization? If Yes.23(a)(7)(iv)(e)) 8.23(a)(7)) Environmental assessment or claim for exclusion (21 CFR 312. Protocol(s) (Continued) d. manufacturing.23(a)(1)) 2. search existing data sources.23(a)(9)) 10. including suggestions for reducing this burden to the address to the right: “An agency may not conduct or sponsor.
Documents Similar To fda 1571
FDA Recommendations on Data Retention
Can Scientists Slow Down Aging_ - Forbes
Inequalities in health care between rich and poor countries
US Grand Jury Indictment Synthes, Inc
Fitzpatrick - Exclusivity and FDA Barriers to Market Entry in the US
More From Nitin Kashyap
6 Uncommon Mistakes That MBA Aspirants Frequently Do
Job Trends - Top Mba
Business School Admissions - George Washington University School of Business Admissions - Part 2
50 Questions to Reach an Ivy League
LOW GPA_ What You Can Do _ the B-School Application
GMP for Pharmaceuticals 6th Ed - Joseph D Nally.pdf
JJ_Thesis[1]
Pda India Chapter Aseptic Processing Workshop Session 2
13 08 09 Promed
000153543
Yogita Final Project